Literature DB >> 17711430

Treatment of pyridostigmine-induced AV block with hyoscyamine in a patient with myasthenia gravis.

Anil Gehi1, Michael Benatar, Jonathan Langberg.   

Abstract

Myasthenia gravis is an autoimmune disorder of the nervous system typically mediated by antibodies against the nicotinic acetylcholine receptor at the neuromuscular junction. Treatment of myasthenia gravis frequently involves the use of cholinesterase inhibitors such as pyridostigmine. Treatment with these agents has been associated with bradycardia and syncope requiring pacemaker implantation. We report a case of a 60-year-old man with a 1-year history of myasthenia gravis treated with pyridostigmine who presented with syncope due to high degree AV block. Before committing the patient to a permanent pacemaker, a trial of medical therapy with hyoscyamine was attempted. Hyoscyamine is a muscarinic antagonist commonly used to block cholinergic side effects associated with pyridostigmine without reducing its efficacy at the neuromuscular junction. Treatment with hyoscyamine resulted in complete resolution of AV block, thereby avoiding pacemaker implantation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17711430     DOI: 10.1111/j.1540-8167.2007.00938.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  3 in total

1.  Pyridostigmine Induced Prolonged Asystole in a Patient with Myasthenia Gravis Successfully Treated with Hyoscyamine.

Authors:  Mohammad Saud Khan; Abhinav Tiwari; Zubair Khan; Himani Sharma; Mohammad Taleb; Jeffrey Hammersley
Journal:  Case Rep Cardiol       Date:  2017-05-14

2.  Pyridostigmine-induced high grade SA-block in a patient with myasthenia gravis.

Authors:  Sarmad Said; Chad J Cooper; Haider Alkhateeb; Sherif Elhanafi; Jorge Bizet; Sucheta Gosavi; Zainul Abedin
Journal:  Am J Case Rep       Date:  2013-09-11

3.  Pyridostigmine induced heart block requiring ICU admission.

Authors:  Benjamin Chaucer; Dustin Whelan; Dronacharya Lamichhane
Journal:  J Community Hosp Intern Med Perspect       Date:  2018-10-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.